Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neutropenia 1Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 26pembrolizumab 24Docetaxel 20Capecitabine 19Fulvestrant 17Trastuzumab 16Anastrozole 15Cyclophosphamide 14Lapatinib 13Letrozole 11Carboplatin 11Radiotherapy 10Doxorubicin 10palbociclib 9Therapeutics 9Nivolumab 9Exercise 9Gemcitabine 8Cisplatin 8Blood Specimen Collection 8Tamoxifen 7Bevacizumab 7liposomal doxorubicin 6exemestane 6abemaciclib 6Vinorelbine 6Standard of Care 6Fluorouracil 6ribociclib 5atezolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Maxy G34 × Breast × Clear all
NCT00501332 2007-12-24

Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy

Maxygen Holdings Ltd.

Phase 2 Unknown
30 enrolled
Breast

Breast Neoplasms, Neoplasms, Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡